Y. Y. Janjigian Et Al. , "Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study," Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain, 2023
Janjigian, Y. Y. Et Al. 2023. Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , (Barcelona, Spain).
Janjigian, Y. Y., Al-Batran, S., Wainberg, Z. A., Van Cutsem, E., Molena, D., Muro, K., ... Hyung, W. J.(2023). Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study . Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain
Janjigian, Y. Et Al. "Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study," Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 2023
Janjigian, Y. Y. Et Al. "Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study." Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain, 2023
Janjigian, Y. Y. Et Al. (2023) . "Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study." Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain.
@conferencepaper{conferencepaper, author={Y. Y. Janjigian Et Al. }, title={Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study}, congress name={Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)}, city={Barcelona}, country={Spain}, year={2023}}